Efficacy of zilucoplan in patients with generalised myasthenia gravis who have not previously received immunoglobulin or plasma exchange: A subgroup analysis from the Phase 3 RAISE study
In the RAISE study, patients without prior immunoglobulin/PLEX, who had milder disease, experienced improvements in MG-specific outcomes with zilucoplan that were comparable to those seen in patients with prior immunoglobulin/PLEX. These findings may support early use of zilucoplan in the gMG treatment paradigm.
Authors
- Kimiaki Utsugisawa (ORCID: https://orcid.org/0000-0001-9373-8167)
- Masayuki Masuda (ORCID: https://orcid.org/0000-0002-6175-8902)
- James F. Howard (ORCID: https://orcid.org/0000-0002-7136-8617)
- Fiona Grimson
- Babak Boroojerdi
Institutions
- University of North Carolina at Chapel Hill (US)
- University of North Carolina Health Care (US)
- Tokyo Medical University (JP)
- National Hospital Organization Hanamaki Hospital (JP)
- UCB Pharma (United Kingdom) (GB)
- UCB Pharma (Germany) (DE)
Publication Details
- Journal
- Journal of the Neurological Sciences
- Published
- 2025-05-16
- DOI
- https://doi.org/10.1016/j.jns.2025.123550
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- UCB